Antidepressants

Venlafaxine 75 mg, n30

International Nonproprietary Name (INN): Venlafaxine

Pharmaceutic group: Antidepressant

Presentation:

Tablets 37.5 mg, 75 mg n30.

Available with prescription

Question?

THERE ARE CONTRAINDICATIONS. CAREFULLY READ THE INSTRUCTIONS FOR USE, OR OBTAIN A SPECIALIST ADVICE

Venlafaxine is indicated for the treatment or prevention of depression. The prescriptions are usually available from a psychiatrist.

Venlafaxine is an orally administered serotonin-norepinephrine reuptake inhibitor (SNRI) class medication with a chemical structure unrelated to that of the known (tricyclic, tetracyclic or other) or other available antidepressant agents. Venlafaxine is available as tablets (usual tablets), containing Venlafaxine HCl (racemic mixture of enantiomers). The mechanism of the antidepressant action of venlafaxine in humans is believed to be associated with its potentiation of neurotransmitter activity in the CNS. Preclinical studies have shown that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine and ODV have no significant affinity for muscarinic, histaminergic, or α-1 adrenergic receptors in vitro. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. Venlafaxine and ODV do not possess monoamine oxidase (MAO) inhibitory activity.

Venlafaxine in the form of usual tablets should be administered, as a rule, twice daily, during the meal, at the equal time points from day to day. Course of treatment is usually rather long, the first signs of depression’s relief show after 1-2 weeks of treatment with the Venlafaxine.

A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.

More information about Venlafaxine’s medical usage you can find in the approved leaflet (in Russian language only), which is included in each carton box of the product.